Kimmtrak(tebentafusp)
Kimmtrak (tebentafusp) is a protein pharmaceutical. Tebentafusp was first approved as Kimmtrak on 2022-01-25. It has been approved in Europe to treat uveal neoplasms.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| eye diseases | D005128 |
Trade Name
FDA
EMA
Kimmtrak
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Tebentafusp
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Kimmtrak | tebentafusp-tebn | Immunocore | N-761228 RX | 2022-01-25 | 1 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| kimmtrak | Biologic Licensing Application | 2024-10-10 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
tebentafusp, Kimmtrak, Immunocore Limited | |||
| 2029-01-25 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9274 | Injection, tebentafusp-tebn, 1 microgram |
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | — | — | 6 | 11 | 2 | — | 1 | 15 |
| Uveal neoplasms | D014604 | EFO_1001230 | — | 3 | 8 | 1 | — | 1 | 10 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tebentafusp |
| INN | tebentafusp |
| Description | Tebentafusp, sold under the brand name Kimmtrak, is an anti-cancer medication used to treat uveal melanoma (eye cancer). Tebentafusp is a bispecific gp100 peptide-HLA-directed CD3 T cell engager. Tebentafusp is given by intravenous infusion.
|
| Classification | Protein |
| Drug class | fusion proteins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1874157-95-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297990 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB15283 |
| UNII ID | N658GY6L3E (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 669 documents
View more details
Safety
Black-box Warning
Black-box warning for: Kimmtrak
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
222 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use